Follow last change Oct 2020 re-read 3 minutes ago

FS-1

Developed for: multidrug-resistant tuberculosis
Investigated by: Invivo laboratory, Kazakhstan · Karaganda Medical University · National Center of Phthisiatry, Bishkek, Kyrgyzstan · National Scientific Center of Phthisiopulmonology, Kazakhstan · Phthisiopulmonology Center of Almaty, Kazakhstan · Scientific Center for Anti-infectious Drugs, Kazakhstan
+2 more
· Semey State Medical University · West Kazakhstan Marat Ospanov Medical University

today NCT02607449 · Ph 3

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT02607449	Dec 2013 → Aug 2020	multidrug-resistant tuberculosis	Scientific Center for Anti-infectious Drugs, Kazakhstan	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	FS-1	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02607449 ↗
Route	Oral	“Study drug was given to the patients orally once per day in dose of 2.5 mg/kg along with other prescribed TB drugs.” NCT02607449 ↗